146 related articles for article (PubMed ID: 24702703)
1. Myasthenia gravis onset during rheumatic disease: a new paradoxical effect of anti-TNF alpha therapy?
Bruzzese V; Marrese C; Scolieri P; Hassan C; Lorenzetti R; Zullo A
Int J Rheum Dis; 2015 Mar; 18(3):375-6. PubMed ID: 24702703
[No Abstract] [Full Text] [Related]
2. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
[TBL] [Abstract][Full Text] [Related]
3. An overview of low disease activity and remission in psoriatic arthritis.
Lubrano E; Perrotta FM; Kavanaugh A
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S51-4. PubMed ID: 26470835
[TBL] [Abstract][Full Text] [Related]
4. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNFα-therapy as an evidence-based treatment option for different clinical manifestations of psoriatic arthritis.
Köhm M; Burkhardt H; Behrens F
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S109-14. PubMed ID: 26472504
[TBL] [Abstract][Full Text] [Related]
6. A review on golimumab in the treatment of psoriatic arthritis.
Urdaneta M; Jethwa H; Sultan R; Abraham S
Immunotherapy; 2017 Sep; 9(11):871-889. PubMed ID: 28838285
[TBL] [Abstract][Full Text] [Related]
7. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
8. Myasthenia gravis after etanercept and ustekinumab treatment for psoriatic arthritis: A case report.
Nicocia G; Bonanno C; Lupica A; Toscano A; Rodolico C
Neuromuscul Disord; 2020 Mar; 30(3):246-249. PubMed ID: 32057636
[TBL] [Abstract][Full Text] [Related]
9. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
Olivieri I; Cortesi PA; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Ciampichini R; Cutro MS; Mathieu A; Matucci-Cerinic M; Punzi L; Scarpa R; Mantovani LG;
Clin Exp Rheumatol; 2016; 34(1):68-75. PubMed ID: 26633622
[TBL] [Abstract][Full Text] [Related]
10. Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study.
De Simone C; Caldarola G; Maiorino A; Tassone F; Campana I; Sollena P; Peris K
Dermatol Ther; 2016 Sep; 29(5):372-376. PubMed ID: 27146358
[TBL] [Abstract][Full Text] [Related]
11. A short history of biological therapy for psoriatic arthritis.
Mease P
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S104-8. PubMed ID: 26472182
[TBL] [Abstract][Full Text] [Related]
12. Continuous versus intermittent therapy for moderate-to-severe psoriasis.
Ramirez-Fort MK; Levin AA; Au SC; Gottlieb AB
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S63-70. PubMed ID: 24129141
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-17 inhibition in psoriatic arthritis.
Boyd T; Kavanaugh A
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S119-23. PubMed ID: 26471234
[TBL] [Abstract][Full Text] [Related]
14. Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis?
Mease P
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S59-62. PubMed ID: 24129140
[TBL] [Abstract][Full Text] [Related]
15. Etanercept-induced Crohn's disease in ankylosing spondylitis: a case report and review of the literature.
Tolu S; Rezvani A; Hindioglu N; Calkin Korkmaz M
Rheumatol Int; 2018 Nov; 38(11):2157-2162. PubMed ID: 30293157
[TBL] [Abstract][Full Text] [Related]
16. Can biologic therapies be withdrawn or tapered in psoriatic arthritis?
Moverley AR; Coates LC; Helliwell PS
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S51-3. PubMed ID: 24129138
[TBL] [Abstract][Full Text] [Related]
17. Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis?
Lubrano E; Soriano E; FitzGerald O
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S54-8. PubMed ID: 24129139
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis.
Johnsson HJ; McInnes IB
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S115-8. PubMed ID: 26471946
[TBL] [Abstract][Full Text] [Related]
19. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
20. Giant orf with prolonged recovery in a patient with psoriatic arthritis treated with etanercept.
Rørdam OM; Grimstad Ø; Spigset O; Ryggen K
Acta Derm Venereol; 2013 Jul; 93(4):487-8. PubMed ID: 23250111
[No Abstract] [Full Text] [Related]
[Next] [New Search]
